Spironolactone start study for heart failure with preserved pumping
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether starting spironolactone helps people with heart failure symptoms when the heart pumps “preserved” (not severely reduced). Participants are assigned to start spironolactone or usual care so researchers can see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older
- You have stable heart failure symptoms for now (your study doctor agrees this fits)
- Your last test within 12 months showed heart pumping of at least 40% (and you may be grouped by 40–49% or 50%+)
- Blood tests show higher heart-stress hormones (NT-proBNP or BNP) at levels set by the study, with special cutoffs if you have atrial fibrillation
- You take a “water pill” called a loop diuretic regularly (most days)
- You have NYHA Class II to IV heart failure symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This study looks at how the heart muscle works in people with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to understand the cause better, which could lead to new treatments.
This study looks at a type of heart failure where the heart pumps normally but is too stiff to fill properly. It aims to better understand and classify this condition, which may help guide future treatments.
This study uses Denmark’s heart failure registry to compare two common tablet medicines—spironolactone and eplerenone—for people with symptomatic systolic heart failure. It aims to see which one leads to better health outcomes over time.
This trial tests a new medicine called finerenone to see if it can reduce heart scarring and improve heart function in people with a certain type of heart failure (preserved ejection fraction). If you qualify, you may help researchers learn if this treatment can help you feel better and stay out of the hospital.
This study tests whether spironolactone, a water pill that helps the heart and blood vessels, can improve symptoms in people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It's a phase 2 trial, meaning it's early but may offer a new treatment option.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.